Sam-A Pharm. Co., Ltd
Financials
Valuation Metrics
Sam-A Pharm. Co., Ltd's Market Cap is ₩866B. At end of 2025 it was ₩1001B. Ranked #1315 of 2,405 in KR market (top 55%), #723 of 1,627 on KOSDAQ (top 44%), #146 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 63%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 86.63B KRW | KR#1,315/2,405 Sec#146/231 |
| Revenue | 72.28B KRW | KR#1,599/2,405 Sec#104/231 |
| Net Income | 10.55B KRW | KR#951/2,405 Sec#60/231 |
| Total Assets | 249.78B KRW | KR#1,140/2,405 Sec#79/231 |
| Net Assets | 229.65B KRW | KR#867/2,405 Sec#60/231 |
| Employees | 316 | KR#760/2,405 Sec#66/231 |
| Value | ||
| P/E | 8.22x | KR#726/2,405 Sec#35/231 |
| P/B | 0.38x | KR#598/2,405 Sec#22/231 |
| P/S | 1.20x | KR#1,547/2,405 Sec#88/231 |
| EV/EBITDA | 12.69x | KR#803/2,405 Sec#45/231 |
| FCF Yield | 10.80% | KR#611/2,405 Sec#25/231 |
| Profitability | ||
| ROE | 4.59% | KR#1,150/2,405 Sec#80/231 |
| ROA | 4.22% | KR#828/2,405 Sec#67/231 |
| Op. Margin | 7.59% | KR#688/2,405 Sec#55/231 |
| Revenue Growth | -12.40% | KR#1,971/2,405 Sec#181/231 |
| Earnings Growth | -31.27% | KR#985/2,405 Sec#63/231 |
| Financial Health | ||
| Debt Ratio | 8.77% | KR#113/2,405 Sec#23/231 |
| Total Debt | 2.62B KRW | KR#1,871/2,405 Sec#182/231 |
| FCF | 9.35B KRW | KR#724/2,405 Sec#40/231 |
| Cash | 19.64B KRW | KR#1,265/2,405 Sec#93/231 |
| Current Ratio | 10.11x | KR#95/2,405 Sec#22/231 |
| Net Debt/EBITDA | -3.10x | KR#153/2,405 Sec#4/231 |
| Dividend | ||
| Div. Yield | 6.28% | KR#194/2,405 Sec#4/231 |
| Div. Growth | 6.25% | KR#648/2,405 Sec#35/231 |
| Performance | ||
| 1Y Return | -18.22% | KR#1,110/2,405 Sec#73/231 |
| 1M Return | -1.81% | KR#439/2,405 Sec#45/231 |
| From 52W High | -20.61% | KR#202/2,405 Sec#11/231 |
| 1Y MDD | -28.98% | KR#205/2,405 Sec#13/231 |
| Trading | ||
| Volume | 3,042 shares | KR#2,210/2,405 Sec#225/231 |
| Trading Value | 41.2M KRW | KR#1,823/2,405 Sec#194/231 |
| Foreign Own. | 2.81% | KR#1,345/2,405 Sec#125/231 |
| Per Share | ||
| EPS | 1,655 KRW | KR#512/2,405 Sec#35/231 |
| BPS | 36,051 KRW | KR#327/2,405 Sec#21/231 |
Company Info
Sama Pharmaceutical, founded as Bogun Pharmaceutical Laboratory in 1945 and incorporated in 1973, was listed on KOSDAQ in 2000. It manufactures and sells a wide range of pharmaceuticals, including respiratory, antibiotic, dermatological, and digestive system drugs, with key products like Citoos, Codenal, Hebron, and Setofen. The company completed its Munmak factory as a KGMP pharmaceutical production facility in 2009 and continues to develop differentiated generic products through new drug and new product research and development. Sama Pharmaceutical is headquartered in Wonju-si, Gangwon-do.